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The medical therapy for inflammatory bowel disease in humans can be difficult but has improved considerably since the introduction of new agents such as ''biologicals.'' 2,3 Antitumor necrosis factor agents such as infliximab have shown to be effective in the management of active disease and as maintenance therapy in patients who have entered symptomatic remission. 4, 5 Some patients, however, have persistent active disease or show loss of efficacy after prolonged treatment. This may be due to the formation of antibodies against infliximab, which is associated with an accelerated clearance of the antibody. In some cases, continuation of treatment with higher dosages results in decreased levels of anti infliximab antibodies. 6, 7 It has been reported that in up to 40% of human patients treated with infliximab, anti-infliximab antibodies are detectable. 7 Adalimumab seems to be less immunogenic; antibodies were detectable in about 10% of patients with RA. 8 Humans and apes share about 99% of their genes; the genetic resemblance between this kind of monkey and humans is not known.
With this case report, we have illustrated the influence of immunogenicity in the formation of antibodies against humanized antitumor necrosis factor, leading to inefficacy of the therapy.
